Displaying 1 - 12 of 20
Immune-Mediated and Cholestatic Diseases
5

GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
7

GSK: "Practical tips towards providing holistic care to patients with PBC" - EASL Congress 2023

View
Viral Hepatitis
5

GSK: “Looking to the future of hepatitis B: how can we achieve functional cure?” - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" - EASL Congress 2023

View
Viral Hepatitis
1

GSK: "Looking To The Future Of Hepatitis B: An Expert Review Of Quantitative Hepatitis B Surface Antigen Assessment” - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" - EASL Congress 2023

View
Viral Hepatitis
5

GSK: “Looking to the future of hepatitis B: how can we achieve functional cure?” - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
5

GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
5

GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023

View
Viral Hepatitis
5

GSK: “Looking to the future of hepatitis B: how can we achieve functional cure?” - EASL Congress 2023

View
Viral Hepatitis
5

GSK: “Looking to the future of hepatitis B: how can we achieve functional cure?” - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
5

GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023

View
Displaying 1 - 12 of 20